Identification of biomarkers for tumor regression grade in esophageal squamous cell carcinoma patients after neoadjuvant chemoradiotherapy
BackgroundEsophageal cancer is a highly invasive malignancy. Neoadjuvant chemoradiotherapy not only increases the rate of complete resection but also improves the median survival. However, a sensitive biomarker is urgently needed in clinical practice.Methods60 esophageal squamous cell carcinoma (ESC...
Saved in:
Main Authors: | Zhifu Chen, Yan Wang, Jun Chen, Zijun Xu, Tingjuan Zhang, Lu Sun, Lihua Zhu, Liben Xu, Chaoyang Wu, Zhiyuan Qiu, Dianjun Wang, Ting Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1426592/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma
by: Xiaofeng Duan, et al.
Published: (2025-01-01) -
Esophageal squamous cell carcinoma with EP300 mutations displays distinct genetic characteristics relevant to neoadjuvant chemoradiotherapy
by: Yutian Lai, et al.
Published: (2025-01-01) -
Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort
by: Wei-Xiang Qi, et al.
Published: (2025-01-01) -
Role of mast cell in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
by: Masaaki Nishi, et al.
Published: (2025-01-01) -
Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study
by: Hai Zhang, et al.
Published: (2025-01-01)